Kura Oncology (NASDAQ:KURA) CEO Purchases $1,239,000.00 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) CEO Troy Edward Wilson acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the acquisition, the chief executive officer owned 479,194 shares of the company’s stock, valued at approximately $5,937,213.66. This trade represents a 26.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Troy Edward Wilson also recently made the following trade(s):

• On Monday, August 17th, Troy Edward Wilson bought 100,000 shares of Kura Oncology stock. The stock was purchased at an average price of $11.12 per share, for a total transaction of $1,112,000.00.

Kura Oncology Trading Down 3.9%

KURA opened at $13.06 on Thursday. The firm’s fifty day moving average is $10.74 and its two-hundred day moving average is $9.58. The firm has a market cap of $1.16 billion, a PE ratio of -3.88 and a beta of 0.38. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Equities research analysts anticipate that Kura Oncology, Inc. will post -3.23 EPS for the current year.

Analyst Upgrades and Downgrades

KURA has been the subject of several recent analyst reports. Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a report on Monday, June 15th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Monday. CLSA set a $24.00 price objective on Kura Oncology in a research report on Thursday, June 4th. Citizens Jmp reissued a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research note on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. IFP Advisors Inc grew its holdings in shares of Kura Oncology by 115.3% during the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after buying an additional 1,284 shares in the last quarter. Allworth Financial LP lifted its stake in Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Kura Oncology by 49.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock valued at $60,000 after acquiring an additional 1,888 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares during the last quarter. Finally, Brevan Howard Capital Management LP acquired a new position in Kura Oncology during the 2nd quarter worth approximately $80,000.

Kura Oncology News Summary

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: CEO Troy Wilson reportedly purchased 100,000 shares for approximately $1.24 million, a sizable open-market investment that investors may interpret as confidence in Kura’s growth prospects. Kura Oncology shares jump after CEO buys $1.24 million of stock
• Positive Sentiment: Analysts continue to express optimism, with Citizens JMP reiterating a “Market Outperform” rating. Broader coverage shows a consensus “Moderate Buy” rating and an average price target of $25.40, materially above recent trading levels. Citizens JMP reiterates Market Outperform rating
• Positive Sentiment: Kura’s commercial outlook is being supported by KOMZIFTI (ziftomenib), which generated $9.1 million in net product revenue over its first two quarters, including 57% sequential growth. Potential expansion into first-line acute myeloid leukemia could substantially increase the addressable market. Phase 1b data are expected in the second half of 2026, with Phase 3 KOMET-017 topline results targeted for 2028. Kura Oncology: Strong Buy and ziftomenib AML expansion prospects
• Positive Sentiment: Recent earnings exceeded expectations: quarterly revenue was $20.87 million versus a $20.16 million consensus estimate, while the per-share loss was narrower than forecast. Institutional ownership also increased, including a large position expansion by California State Teachers’ Retirement System.
• Neutral Sentiment: The company remains unprofitable, with analysts expecting a full-year loss, so valuation remains dependent on continued KOMZIFTI sales growth and successful clinical development.
• Negative Sentiment: Insider Brian Powl sold 4,345 shares worth approximately $51,662. The sale was relatively small and reduced his holdings by 2.5%, but it contrasts with the CEO’s much larger purchase. Kura Oncology insider share sale

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.